로딩 중…
지수 로딩 중…
Biohaven Ltd.
BHVN· NYSE· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$15.14-1.78%
2026-11-02
Financials
Valuation Metrics
Biohaven Ltd.'s Market Cap is $2.28B. At end of 2025 it was $1.36B. Ranked #1876 of 3,118 in US market (top 60%), #1190 of 1,644 on NYSE (top 72%), #119 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 45%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.28B | US#1,876/3,118 Sec#119/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-543M | US—/3,118 Sec—/265 |
| Total Assets | $264M | US#2,859/3,118 Sec#193/265 |
| Net Assets | $-98M | US#2,895/3,118 Sec#236/265 |
| Employees | 274 | US#2,422/3,118 Sec#114/265 |
| Value | ||
| FCF Yield | -20.75% | US—/3,118 Sec—/265 |
| Financial Health | ||
| Total Debt | $300M | US#2,088/3,118 Sec#78/265 |
| FCF | $-473M | US#2,905/3,118 Sec#254/265 |
| Cash | $96M | US#1,597/3,118 Sec#96/265 |
| Current Ratio | 3.05x | US#498/3,118 Sec#149/265 |
| Performance | ||
| 1Y Return | -11.95% | US#2,161/3,118 Sec#169/265 |
| 1M Return | 17.68% | US#404/3,118 Sec#26/265 |
| From 52W High | -18.44% | US#1,304/3,118 Sec#68/265 |
| 1Y MDD | -56.99% | US#2,647/3,118 Sec#192/265 |
| Trading | ||
| Volume | 1,612,342 shares | US#734/3,118 Sec#60/265 |
| Trading Value | $25M | US#1,433/3,118 Sec#94/265 |
| Per Share | ||
| EPS | $-3.60 | US—/3,118 Sec—/265 |
| BPS | $-0.65 | US#2,791/3,118 Sec#233/265 |
Company Info
Biohaven Ltd. operates as a biopharmaceutical firm actively engaged in clinical trials. Its primary objective is to advance innovative treatments for disorders affecting the nervous and immune systems, with the potential to transform current medical interventions.